Alexandros Polymeris, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 37 | 2023 | 9694 | 1.870 |
Why?
|
Brain Ischemia | 19 | 2023 | 3047 | 1.470 |
Why?
|
Atrial Fibrillation | 19 | 2024 | 5103 | 1.400 |
Why?
|
Anticoagulants | 23 | 2024 | 4777 | 1.040 |
Why?
|
Antifibrinolytic Agents | 2 | 2023 | 292 | 0.730 |
Why?
|
Tranexamic Acid | 1 | 2023 | 176 | 0.730 |
Why?
|
Hemostatics | 1 | 2023 | 242 | 0.720 |
Why?
|
Thrombolytic Therapy | 7 | 2022 | 2060 | 0.670 |
Why?
|
Cerebral Hemorrhage | 11 | 2024 | 2650 | 0.650 |
Why?
|
Thromboembolism | 2 | 2024 | 996 | 0.590 |
Why?
|
Administration, Oral | 12 | 2024 | 3991 | 0.560 |
Why?
|
Ischemic Attack, Transient | 5 | 2022 | 878 | 0.550 |
Why?
|
Intracranial Hemorrhages | 9 | 2023 | 820 | 0.520 |
Why?
|
Medication Adherence | 5 | 2024 | 2155 | 0.520 |
Why?
|
Cerebrovascular Disorders | 2 | 2019 | 1475 | 0.460 |
Why?
|
Spastic Paraplegia, Hereditary | 1 | 2016 | 168 | 0.440 |
Why?
|
Vertebral Artery Dissection | 2 | 2024 | 51 | 0.410 |
Why?
|
Adenosine Triphosphatases | 1 | 2016 | 832 | 0.390 |
Why?
|
GTP-Binding Proteins | 1 | 2016 | 950 | 0.390 |
Why?
|
Secondary Prevention | 4 | 2024 | 1474 | 0.370 |
Why?
|
Vitamin K | 4 | 2021 | 318 | 0.370 |
Why?
|
Fibrinolytic Agents | 8 | 2024 | 2071 | 0.320 |
Why?
|
Aged, 80 and over | 24 | 2024 | 58683 | 0.310 |
Why?
|
Seizures | 1 | 2019 | 2919 | 0.270 |
Why?
|
Cerebral Amyloid Angiopathy | 2 | 2023 | 892 | 0.250 |
Why?
|
Recovery of Function | 3 | 2020 | 2970 | 0.250 |
Why?
|
Hematoma | 3 | 2024 | 768 | 0.230 |
Why?
|
Switzerland | 5 | 2022 | 323 | 0.210 |
Why?
|
Disability Evaluation | 2 | 2022 | 1825 | 0.200 |
Why?
|
Leukopenia | 1 | 2022 | 211 | 0.190 |
Why?
|
Siderosis | 1 | 2022 | 103 | 0.190 |
Why?
|
Carotid Artery, Internal, Dissection | 1 | 2021 | 42 | 0.180 |
Why?
|
Aspirin | 2 | 2024 | 3131 | 0.180 |
Why?
|
Muscle Tonus | 1 | 2020 | 82 | 0.180 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 72 | 0.180 |
Why?
|
Cerebral Arterial Diseases | 1 | 2019 | 82 | 0.170 |
Why?
|
Male | 32 | 2024 | 358747 | 0.170 |
Why?
|
Aged | 28 | 2024 | 168218 | 0.160 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5649 | 0.160 |
Why?
|
Membrane Proteins | 1 | 2016 | 7843 | 0.160 |
Why?
|
Hyponatremia | 1 | 2022 | 279 | 0.160 |
Why?
|
Hemorrhage | 5 | 2024 | 3400 | 0.160 |
Why?
|
Gait Disorders, Neurologic | 1 | 2020 | 238 | 0.150 |
Why?
|
Humans | 51 | 2024 | 758406 | 0.150 |
Why?
|
Prospective Studies | 15 | 2024 | 54137 | 0.150 |
Why?
|
Female | 31 | 2024 | 390323 | 0.150 |
Why?
|
Thrombocytopenia | 2 | 2022 | 1171 | 0.140 |
Why?
|
Dimethyl Sulfoxide | 1 | 2017 | 251 | 0.140 |
Why?
|
Cryoprotective Agents | 1 | 2017 | 128 | 0.140 |
Why?
|
Atherosclerosis | 2 | 2023 | 3401 | 0.140 |
Why?
|
Sodium | 1 | 2022 | 1588 | 0.130 |
Why?
|
Greece | 1 | 2016 | 336 | 0.130 |
Why?
|
Self Administration | 1 | 2016 | 390 | 0.120 |
Why?
|
Treatment Outcome | 13 | 2024 | 64378 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17768 | 0.120 |
Why?
|
Recombinant Proteins | 1 | 2024 | 6520 | 0.120 |
Why?
|
Deglutition Disorders | 1 | 2019 | 625 | 0.110 |
Why?
|
Enteral Nutrition | 1 | 2019 | 785 | 0.110 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2022 | 2747 | 0.100 |
Why?
|
Metformin | 1 | 2020 | 907 | 0.100 |
Why?
|
Cryopreservation | 1 | 2017 | 717 | 0.100 |
Why?
|
Mutation | 1 | 2016 | 29915 | 0.100 |
Why?
|
Tissue Plasminogen Activator | 1 | 2017 | 1156 | 0.090 |
Why?
|
Drug Monitoring | 1 | 2017 | 960 | 0.090 |
Why?
|
Emergency Medical Services | 2 | 2019 | 1915 | 0.090 |
Why?
|
Middle Aged | 18 | 2024 | 219568 | 0.090 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1930 | 0.090 |
Why?
|
Cohort Studies | 9 | 2024 | 41256 | 0.090 |
Why?
|
Risk Factors | 10 | 2023 | 73809 | 0.090 |
Why?
|
Registries | 4 | 2022 | 8175 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2020 | 2768 | 0.080 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39059 | 0.080 |
Why?
|
Thrombectomy | 2 | 2023 | 690 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2019 | 2782 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4106 | 0.070 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3069 | 0.070 |
Why?
|
Prognosis | 4 | 2019 | 29557 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2023 | 2048 | 0.070 |
Why?
|
Sex Characteristics | 1 | 2017 | 2621 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15785 | 0.060 |
Why?
|
Recurrence | 3 | 2021 | 8426 | 0.050 |
Why?
|
Factor Xa | 1 | 2024 | 167 | 0.050 |
Why?
|
Retrospective Studies | 8 | 2024 | 80168 | 0.050 |
Why?
|
Brain | 2 | 2019 | 26947 | 0.050 |
Why?
|
Time Factors | 5 | 2022 | 39872 | 0.050 |
Why?
|
Heart Valves | 1 | 2023 | 284 | 0.050 |
Why?
|
Phenprocoumon | 1 | 2021 | 20 | 0.050 |
Why?
|
Acenocoumarol | 1 | 2021 | 19 | 0.050 |
Why?
|
Pleura | 1 | 2023 | 244 | 0.050 |
Why?
|
Leukocytosis | 1 | 2022 | 251 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2017 | 5129 | 0.040 |
Why?
|
Disease Progression | 1 | 2016 | 13468 | 0.040 |
Why?
|
Germany | 1 | 2021 | 868 | 0.040 |
Why?
|
Denmark | 1 | 2021 | 759 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13245 | 0.040 |
Why?
|
Administration, Intravesical | 1 | 2018 | 92 | 0.040 |
Why?
|
Intubation, Gastrointestinal | 1 | 2019 | 166 | 0.040 |
Why?
|
Thrombocytosis | 1 | 2018 | 81 | 0.040 |
Why?
|
Deglutition | 1 | 2019 | 208 | 0.040 |
Why?
|
Atrophy | 1 | 2022 | 1627 | 0.040 |
Why?
|
Chromogenic Compounds | 1 | 2017 | 31 | 0.040 |
Why?
|
Adult | 8 | 2024 | 219935 | 0.040 |
Why?
|
Gastrostomy | 1 | 2019 | 321 | 0.030 |
Why?
|
Heparin | 1 | 2023 | 1632 | 0.030 |
Why?
|
Platelet Count | 1 | 2018 | 775 | 0.030 |
Why?
|
Risk Assessment | 3 | 2023 | 23884 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 842 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 4 | 2024 | 36284 | 0.030 |
Why?
|
Patient Admission | 1 | 2022 | 1372 | 0.030 |
Why?
|
Child, Preschool | 1 | 2016 | 42062 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4839 | 0.030 |
Why?
|
Warfarin | 1 | 2021 | 1482 | 0.030 |
Why?
|
Sex Factors | 1 | 2024 | 10504 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2307 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25956 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9599 | 0.020 |
Why?
|
Acute Disease | 1 | 2019 | 7225 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3433 | 0.020 |
Why?
|
Hospitals | 1 | 2022 | 3887 | 0.020 |
Why?
|
Child | 1 | 2016 | 79818 | 0.020 |
Why?
|
Adolescent | 1 | 2016 | 87892 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9267 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22029 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5199 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 3992 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15651 | 0.020 |
Why?
|
Blood Pressure | 1 | 2021 | 8451 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20055 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12721 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10112 | 0.020 |
Why?
|
Electrocardiography | 1 | 2016 | 6363 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18358 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 21272 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8611 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20500 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12075 | 0.010 |
Why?
|
United States | 1 | 2022 | 72136 | 0.010 |
Why?
|